When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
FOLD - Amicus completes enrollment in late-stage study of AT-GAA in Pompe disease
Amicus Therapeutics Inc.
Amicus Therapeutics (FOLD-0.5%) announces that it completed enrollment last quarter in its Phase 3 clinical trial, PROPEL, evaluating chaperone replacement therapy AT-GAA in patients with an inherited metabolic disorder called Pompe disease, characterized by the buildup of glycogen in cells leading organ dysfunction. AT-GAA has Breakthrough Therapy status for the indication.
More news on: Amicus Therapeutics, Inc., Healthcare stocks news,